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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ Lowered plasma concentrations of
artesunate have been reported in
uncomplicated malaria in pregnancy which
could risk the life of the mother and fetus.
￿ The reason for lowered plasma
concentrations in pregnancy is unexplained.
￿ Oral artesunate is hydrolyzed rapidly in the
stomach to the biologically active
metabolite dihyroartemisinin.
WHAT THIS STUDY ADDS
￿ Following i.v.artesunate administration for
malaria in pregnancy the disposition of
artesunate and dihydroartemisinin were
similar to controls (the same women studied
post partum without malaria).
￿ Higher concentrations of artesunate and
dihydroartemisinin were observed after oral
administration i.e the disease reduced the
pre-systemic metabolism of artesunate.
￿ This study did not conﬁrm previous reports
and is reassuring regarding current dosing
for artesunate in pregnancy.
AIM
To determine if reported lower plasma concentrations of artemisinin derivatives
for malaria in pregnancy result from reduced oral bioavailability,expanded
volume of distribution or increased clearance.
METHODS
In a sequentially assigned crossover treatment study,pregnant women with
uncomplicated falciparum malaria received i.v.artesunate (i.v.ARS) (4 mg kg
-1)
on the ﬁrst day and oral ARS (4 mg kg
-1) on the second,or,oral on the ﬁrst and
i.v.on the second,in both groups followed by oral ARS (4 mg kg
-1 day-1) for 5
days.Plasma concentrations of ARS and dihyroartemisinin (DHA) were measured
by liquid chromatography-mass-spectrometry on days 0,1,2 and 6.Controls
were the same women restudied when healthy (3 months post partum).
RESULTS
I.v.ARS administration resulted in similar ARS and DHA pharmacokinetics in
pregnant women with malaria (n = 20) and in controls (n = 14).Oral
administration resulted in higher total drug exposure in pregnancy [AUC (95%
CI) in (ng ml
-1 h)/(mg kg-1)] of 55.1 (30.1,100.0) vs. 26.5 (12.2,54.3) for ARS,P =
0.002 and 673 (386,1130) vs. 523 (351,724) for DHA,P = 0.007.The
corresponding median absolute oral bioavailability (F%) was 21.7 (12.6,75.1) vs.
9.9 (6.0,36.81) for ARS (P = 0.046) and 77.0 (42.2,129) vs. 72.7 (42.0,87.7) for
DHA,P = 0.033.Total DHA exposure was lower at day 6 in pregnant women with
malaria (P < 0.001) compared with day 0 or 1,but not in the controls (P = 0.084).
CONCLUSIONS
This study demonstrates the effects of malaria on oral ARS drug disposition are
greater than those of pregnancy.This probably results from a disease related
reduction in ﬁrst pass metabolism.The data are reassuring regarding current
dosing recommendations.
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The pharmacokinetic properties of many antimalarials are
altered during pregnancy [1].There is often an expanded
apparent volume of distribution and increased clearance
resulting in lower drug exposure which contributes to
higher treatment failure rates.In low transmission settings
treatment responses to antimalarial drug regimens are
worse in pregnant women than in age-matched women
from the same location who are not pregnant [2].The arte-
misinin derivatives are now central to the treatment of
falciparum malaria and artemisinin combination treat-
ments are recommended in the second and third trimes-
ters of pregnancy. Previous studies have suggested that
plasma concentrations of the artemisinin derivatives and
theircommonactivemetabolitedihydroartemisinin(DHA)
are low in pregnancy [3, 4]. Finding the correct dose of
artesunate (ARS) in pregnancy is necessary not only to
obtainoptimalcureratesfortheindividualpatientbutalso
to limit the emergence and spread of resistance [5].
The recommendations for dosing of ARS and artemisi-
nin based combination therapies were based initially on
Chinese studies with different dosing durations and were
modiﬁed by later pharmacodynamic assessments in non-
immune patients with uncomplicated falciparum malaria
[6].ARS is rapidly hydrolyzed in vivo to DHA which also has
antimalarial activity [7]. There are three pharmacokinetic
studies of artemisinin derivatives in pregnant women [4,8,
9]. One reports ARS and DHA pharmacokinetics using
liquid chromatography-mass-spectrometry (LC-MS) in 24
pregnant women with acute uncomplicated P. falciparum
malaria treated with oral ARS 4 mg kg
-1 day
-1 (and
atovaquone-proguanil) [4]. DHA maximum concentration
and drug exposure were 4.2- and 1.8-fold lower in preg-
nant women compared with non-pregnantThai adults (17
males, three females) with acute uncomplicated malaria
given approximately half the dose (1.79 mg kg
-1) [10].The
corresponding estimates of the apparent volumes of dis-
tribution and oral clearance were 2.3- and 2.7-fold higher
inpregnantwomencomparedwithThaiadults[10].Similar
ﬁndings were reported for artemether given as
artemether-lumefantrine (Coartem®) for uncomplicated P.
falciparum [3, 4]. The maximum concentration and expo-
sure for artemether were lower by approximately 1.9- and
3.2-fold and for DHA, 1.2 and 1.6 fold, in 13 pregnant
women[3]comparedwith25adultmaleThaipatientswith
acute uncomplicated falciparum malaria [11].The relative
contributions of decreased absorption or increased clear-
ance or volume of distribution to the reductions in plasma
concentrations were not quantiﬁed. Furthermore the
earlier studies were carried out before some major sources
of preventable errors in measuring ARS and DHA were dis-
covered [12]. Thermolability of ARS and DHA, haemolytic
products related to sample collection and malaria infec-
tion in combination with organic solvents during sample
processing have been shown to cause ex vivo degradation
of ARS and DHA resulting in apparently lowered plasma
concentrations [12].Recently,two publications originating
from a single study reported on the disposition of ARS and
DHA comparing pregnant women with malaria, the same
women post partum without malaria and a control group
of non-pregnant women with malaria [8, 9]. The results
were at odds depending on which group was used as a
control. The non-compartmental pharmacokinetic analy-
sis, showed DHA exposure to be less when comparing
pregnant women with malaria and the same women
studied post partum after oral ARS,but the difference was
not statistically different [9]. However, when compared
with non-pregnant controls with malaria, DHA exposure
was signiﬁcantly lower in pregnant women with malaria.
The report using a population modelling approach
excludeddatafrompostpartumwomenbecauseoferratic
ARSabsorption,whichmadeitdifﬁculttoidentifyapredic-
tive structural model to describe the data. The analysis
indicated a 42.3% increase in DHA clearance in pregnant
women compared with non-pregnant controls. The
authors concluded that dosing in pregnant women with
malaria needed to be revised [8].
The aim of this project was to characterize ARS and
DHA pharmacokinetics deﬁnitively following intravenous
administration of ARS and thereby determine whether
reduced oral absorption or increased distribution and
elimination affected plasma concentrations of ARS and
DHAinpregnantwomenwithuncomplicatedP.falciparum
infections.
Methods
Subjects
Twentypregnantwomen(secondandthirdtrimester)with
acute uncomplicated falciparum malaria, participated in
the study after having given written informed consent or
thumb print if the patient was unable to read or write.This
study took place in the clinics of the Shoklo Malaria
Research Unit on the North Western border of Thailand.
Enrolment commenced in April 2008 and the last post
partum sampling was in March 2009.
Since 1986,when malaria was the main cause of mater-
naldeathinthisarea,theShokloMalariaResearchUnithas
run a weekly antenatal clinic programme to detect and
treat all parasitaemic episodes during pregnancy, to
preventmalariamortalityandreducemorbidity[13].Blood
smears are taken for the detection of malaria parasites at
each visit. At the time of protocol submission falciparum
malaria in the second and third trimesters of pregnancy
was routinely treated witha7d a yc ourse of ARS.Anaemic
women(haematocrit<25%)werenoteligibleforinclusion.
Ethical approval
ApprovalforthestudywasgrantedbytheFacultyofTropi-
cal Medicine,Mahidol University Ethics Committee (TM-IR
R.McGready et al.
468 / 73:3 / Br J Clin Pharmacol029/2005) and OxfordTropical Research Ethics Committee
(OXTREC 007-05).
Study design
Consecutively enrolled pregnant women were assigned
alternatively to the two groups. Group 1 treatment com-
menced with i.v. ARS while group 2 started with oral ARS
and received the i.v. ARS dose the next day. Each group
received the same total dose of ARS as follows:
Group 1: i.v. ARS (Guilin Pharmaceutical Factory,
Guangxi, China repackaged in Thailand by Atlantic Phar-
maceuticals) 4 mg kg
-1 on day 0 followed by oral ARS
4m gk g
-1 orally for 6 days or,
Group 2:oral artesunate (Guilin Pharma,Guilin,Peoples
RepublicofChinarepackagedinThailandbyAtlanticPhar-
maceuticals) 4 mg kg
-1 on day 0 followed by i.v. ARS
4m gk g
-1 on day 1 followed by oral artesunate 4 mg kg
-1
daily for 5 days.Oral treatment was directly observed and
given with water.
The same women were restudied in a healthy state 3
months post partum and were prescribed the same treat-
ment regimen.
In the post partum period women were followed
monthly. At 3 months post partum, each woman was
examined by a physician and screened for malaria. If she
was unwell, e.g. malaria, or any other illness, this was
treated and the sampling was postponed to a later date.
Sampling regimen
In group 1, 2 ml of blood was drawn at baseline on day 0
andthenat5,15,30,60,120,180,240and360 minafterthe
i.v.dose and on day 1 at baseline and after the oral dose at
15,30,60,90,120,180,240 and 360 min.
In group 2,2 ml of blood was drawn at baseline on day
0 and then at 15,30,60,90,120,180,240 and 360 min after
the oral dose and at 5,15,30,60,120,180,240 and 360 min
after the i.v.dose on day 1.
In both groups on day 6, 2 ml samples were obtained
before (baseline) and after the oral dose at 60, 120 and
240 min.
Blood samples were collected into 2 ml tubes contain-
ing sodium ﬂuoride/potassium oxalate as an anticoagu-
lant. The tubes were pre-chilled on wet ice prior to use.
After inverting the tube ﬁve to six times to ensure mixing
the tube was placed directly back onto the wet ice and
processedassoonaspossibleaftercollection.Wholeblood
was centrifuged at 4°C,2000 g for 7 min to obtain plasma.
Immediately after centrifugation, the plasma was trans-
ferred into a screw cap cryovial (Nalgene No. 5000 0012)
and frozen in liquid nitrogen. The sampling and storage
time were recorded and a note made in the case of visible
haemolysis.
Samples were transferred to the main laboratory daily
where they were stored at -80°C. After all samples were
collectedtheyweretransferredondryiceforARSandDHA
drug analysis at the Clinical Pharmacology Laboratory,
MORU, Bangkok, Thailand [14].. ARS and DHA were
quantiﬁed with liquid chromatography-tandem mass-
spectroscopy [14]. This analytical method has been vali-
dated according to USA FDA guidelines. As stipulated by
USAFDAguidelines,qualitycontrolsamplesatlow,middle
andhighconcentrationwereanalyzedwithineachanalyti-
cal batch to ensure accuracy and precision during analysis.
The total assay coefﬁcients of variation were less than 8%
at every level for this study.The lower limit of quantiﬁca-
tion (LLOQ) was 1.2 ng ml
-1 for ARS and 2.0 ng ml
-1 for
DHA.
Pharmacokinetic analysis
Individual concentration–time data were evaluated using
a non-compartmental analysis approach in WinNonlin
version 5.0 (Pharsight Corporation, California, USA). Total
drug exposure up to the last measured concentration
(AUC(0,last)) was calculated using the linear trapezoidal
method for ascending concentrations and the logarithmic
trapezoidal method for descending concentrations. Drug
exposurewasextrapolatedfromthelastobservedconcen-
trationtotimeinﬁnitybyClast/lZforeachindividualsubject
to compute total drug exposure (AUC(0,•)). The terminal
elimination half-life (t1/2) was estimated by log-linear
regression of three to six concentrations in the terminal
eliminationphase.Maximumconcentration(Cmax)andtime
to maximum concentration (tmax) were taken directly from
the observed data. Apparent volume of distribution (VD)
and clearance (CL) were computed individually according
to standard procedures. Complete in vivo conversion of
ARS into DHA was assumed and the administered dose of
DHA was calculated by adjusting for the difference in
molecular weight.Individual values of dose-adjusted total
drug exposure after oral administration divided by dose-
adjusted total drug exposure after i.v.administration were
used to calculate absolute oral bioavailability (F).
Individual pharmacokinetic parameter estimates and
individual ARS and DHA concentrations at day 0,day 1 and
day6wereinvestigatedinbothpregnantandpostpartum
women using data collected at the same time points (i.e.1,
2,4and6 hafterdose)toevaluatethemagnitudeofmeta-
bolic auto-induction and/or a possible disease effect.
Statistical analysis
Pharmacokinetic parameter estimates for the pregnant
women with malaria were compared with estimates for
the same women when studied post partum and without
malaria using the Wilcoxon matched-pairs signed-ranks
test in STATA v.10. Individual ratios (pregnant : post
partum) of parameter estimates for each woman were cal-
culated and summarized to illustrate trends and the direc-
tion of signiﬁcant differences. Comparisons were made
using Mann-Whitney U-test for non-parametric data. All
women were categorized into two groups ‘mildly unwell’
and‘moderately unwell’on the basis of admission labora-
tory and clinical ﬁndings. Women with raised (25
th
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(25
thcentile)liverfunctiontests,includingbilirubin(total
or direct), aspartate aminotransferase or alanine ami-
notransferase, or fever (37.5°C) and tachycardia (>100
beats min
-1) were categorized as moderately unwell,and if
none of these conditions was satisﬁed,mildly unwell.
Efﬁcacy and safety assessment
Afullmedicalhistoryandexamination(includingobstetric
evaluation) was carried out by a physician and a midwife.
Gestational age of the pregnancy was obtained from a
routineultrasoundobtainedatthewoman’sﬁrstantenatal
consultation and fetal viability conﬁrmed by ultrasound.
Complete blood count, biochemistry and parasite count
weremeasuredonadmission.Bloodsmears(thinandthick
ﬁlms) were prepared using Giemsa staining and were read
for200ﬁeldsbeforebeingdeclarednegative.Parasiteden-
sities were counted per 500 white blood cells or per 1000
red blood cells (RBC) and expressed as parasites per
microlitre. A total of 200 high powered ﬁelds on the
thick ﬁlm were read before declaring a smear negative.All
stages of the parasites were recorded (asexual and game-
tocytes).Threespotsofbloodonﬁlterpaperwereobtained
for PCR genotyping using the method described by Brock-
man and colleagues [15] using MSP1,MSP2 and GLURP to
differentiate recrudescent and novel infections.
Daily malaria smears and temperature measurements
were made for assessment of parasite clearance. Patients
had a daily evaluation including: clinical and obstetric
examination,drug administration and recording of subjec-
tiveandobjectivesideeffectsonacaserecordform.There-
afterwomenwereseenweeklyfor63daysoruntildelivery,
whichever occurred later. Anaemia (haematocrit <30%)
was screened for each week for 63 days and thereafter
every second week. Anaemic women received ferrous
sulphate and folic acid supplements.
In the case of reappearance of falciparum parasites
during the follow-up period a PCR blood spot sample was
obtained and the patient was treated with ARS (2 mg kg
-1
day
-1;50 mg tablets Guilin Pharma,Guilin,Peoples Repub-
licofChinarepackagedinThailandbyAtlanticPharmaceu-
ticals) and clindamycin (300 mg three times daily; 300 mg
capsulefromSiamPharmaceuticalCompanyLtd,Bangkok,
Thailand) both for 7 days and followed up weekly for 6
weeks or until delivery.
All women were asked to deliver in the Shoklo Malaria
ResearchUnitobstetricfacilityanddataonpregnancyout-
comeswerecollectedincludinggender,birthweight(Elec-
tronic SECA medical: scales, precision 10g) and labour
complications. Each baby was examined by a trained
physician for the presence of congenital abnormalities.
Mothersandtheirbabieswereinvitedtomonthlyfollow-up
visits and their infants were assessed for motor and neuro-
logicaldevelopment,accordingtothemethodsdeveloped
and validated at this site and described previously [16].
Results
Twenty-one pregnant women were enrolled. One patient
withdrew consent before any sampling or drug adminis-
tration took place and she has not been included in the
analysis.Women who received the oral drug ﬁrst (group 2)
were a mean of 6 years older and, as a consequence, had
Table 1
Baseline characteristics of women in groups 1 (ﬁrst dose i.v.) and 2 (ﬁrst dose oral),and according to disease severity
Characteristic
Group 1-i.v. ﬁrst
n = 10
Group 2-Oral ﬁrst
n = 10 P value
Moderately unwell
n = 13
Mildly unwell
n = 7 P value
Age (years) 24 (17–40) 32 (22–40) 0.052 25 (17–40) 27 (25–40) 0.275
Gravidity 1 (1–6) 4 (1–8) 0.043 1 (1–8) 4 (1–6) 0.438
Parity 0 (0–5) 2 (0–6) 0.052 0 (0–6) 2 (0–5) 0.351
Primigravida (%) (n) 60 (6/10) 20 (2/10) 0.170 53.8 (7/13) 14.3 (1/7) 0.158
Smoker % (n) 20.0 (2/10) 20.0 (2/10) 1.000 7.7 (1/13) 42.9 (3/7) 0.101
Body weight (kg) 48 (40–59) 50 (40–64) 0.315 48 (40–64) 50 (42–59) 0.643
Body mass index (kg m-2) 19.8 (17.3–24.2) 20.9 (18.8–25.3) 0.190 20.4 (17.3–25.3) 19.8 (19.2–24.2) 0.588
Temperature (°C) 37.8 (36.0–40.0) 37.1 (36.1–39.0) 0.853 38 (36.2–40.0) 36.2 (36.0–37.8) 0.005
Febrile (%) (n) 60.0 (6/10) 40.0 (4/10) 0.656 69.2 (9/13) 14.3 (1/7) 0.057
History fever (%) (n) 100.0 (10/10) 90.0 (9/10) 1.000 100.0 (13/13) 85.7 (6/7) 0.350
Fever (days) 2 (1–7) 3 (1–4) 0.604 2 (1–7) 1.5 (1–3) 0.210
Gestational age (weeks) 24.8 (17.1–33.5) 25.5 (14.0–37.4) 0.912 24 (14–37) 25 (14–34) 0.699
Third trimester (%) (n) 40.0 (4/10) 50.0 (5/10) 1.000 46.2 (6/13) 42.9 (3/7) 1.00
Haematocrit (%) 30 (25–46) 30 (27–34) 0.625 30 (25–34) 32 (27–46) 0.938
Anaemic (%) (n) 33.0 (4/9) 40.0 (4/10) 1.000 50.0 (6/12) 28.6 (2/7) 0.633
GM parasitaemia (/ml) 7 993 (575–63 096) 2 864 (129–51 286) 0.317 6 281 (288–51 286) 1 792 (129–63 096) 0.277
Moderately unwell (%) (n) 70% (7/10) 60% (6/10) 1.000 n.a n.a n.a
Data are median (range) or proportion % (n).
R.McGready et al.
470 / 73:3 / Br J Clin Pharmacolhigher gravidity and parity (Table 1). The remaining
admission characteristics were not signiﬁcantly different
(Table 1). As expected women who returned for post
partum sampling (malaria smear negative) had signiﬁ-
cantly lower temperature,pulse rate,respiratory rate,body
mass index and higher blood pressure and haematocrit on
individual paired testing (P < 0.05 for all,data not shown).
Based on the criteria described above 13 women were
in the moderately unwell group and seven were in the
mildly unwell group. Apart from fever, which was one of
the differentiating criteria,there were no other signiﬁcant
demographic differences between the two groups
(Table 1).
Pharmacokinetics
ARSandDHApharmacokineticswerewellcharacterizedin
pregnant women with malaria and in the same women
postpartuminahealthystate,withthedesignedsampling
schedule (Figures 1 and 2, Table 2A,B).There were no sig-
niﬁcant differences in ARS or DHA pharmacokinetics
between pregnant women with malaria compared with
the same women restudied post partum in a healthy state
afteri.v.administrationofARS.Bycontrastafteroraladmin-
istration, pregnant women with malaria had signiﬁcantly
higher total drug exposure (AUC) than the same women
post partum in a healthy state (PARS = 0.002, PDHA = 0.007)
(Table 2B). The median absolute oral bioavailability (F%)
assessed by comparison of AUCs following oral and i.v.
administration was 21.7% for ARS and 77.0% for DHA in
pregnant women with uncomplicated falciparum malaria
(Table 2B) compared with 9.9% for ARS (P = 0.046) and
72.7% for DHA (P = 0.033) in the the same women post
partum in a healthy state (Table 2B). This increased bio-
availability resulted in signiﬁcantly lower estimates for oral
clearance (CL/F, PARS = 0.002, PDHA = 0.013) and apparent
volumeofdistribution(V/F,P DHA=0.0330)afteroraladmin-
istration (Table 2B).The low bioavailability of ARS conﬁrms
a major pre-systemic metabolism and/or breakdown of
ARS into DHA after oral administration.
There were no signiﬁcant differences in derived ARS or
DHA pharmacokinetic variables between day 0 and day 1
after i.v. or oral administration in pregnant women with
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Figure 1
Artesunate and dihydroartemisinin plasma concentration–time proﬁles in pregnant women with uncomplicated falciparum malaria and in the same
women post partum in a healthy state
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cantly lower total DHA exposure at day 6 compared with
day 0 and day 1 after repeated oral administration of ARS
in pregnant women with malaria (Figure 2,Table 3) which
was not seen in the same women post partum in a healthy
state.There were insufﬁcient data points above the LOQ to
perform a non-compartmental analysis for ARS but indi-
vidualdrugconcentrationsatday0andatday1compared
withdrugconcentrationsatday6showthesameeffectfor
ARS as for DHA in pregnant women with malaria. There
were no signiﬁcant differences in individual ARS concen-
trations at day 0 and at day 1 compared with day 6 for the
same women post partum in a healthy state.These results
suggest that a disease effect is a more likely explanation
thanmetabolicauto-inductionfortheﬁndingsinthepreg-
nant group with acute malaria.
The antimalarial effect derives both from ARS and its
metabolite DHA. There was a signiﬁcantly higher com-
bined drug exposure of ARS and DHA after oral (P < 0.001)
and i.v.(P = 0.001) treatment in women who were moder-
ately unwell compared with women who were mildly
unwell (Table 4,Figure 3).
Efﬁcacy and adverse effects
Of the 20 treated women eight remained free of parasites
by day 63 of follow-up (median days 42 (7–68) days).The
remainder had recurrence of malaria, although this was
mainly P. vivax malaria: 10 P. vivax, one P. falciparum and
one mixed (P. falciparum and P. vivax) infection. The
mediantimetoreappearanceforP. falciparum(andmixed)
infection was 35 (28–42) days and for P. vivax was 31 (21–
56)days.Overallfourofthe20womenhadareappearance
of P. falciparum before day 63 but three of these women
had a P. vivax infection before their P. falciparum infection.
PCR genotyping of these P. falciparum infections con-
ﬁrmed that two were recrudescent and two were novel
infections.Usingsurvivalanalysisthecureratebyday63of
ARS (4 mg kg
-1 day
-1 for 7 days) for P. falciparum infection
was 86.9% (95% CI 69.8,100) and for any reappearance of
malaria was 29.6% (95% CI 5.1,54.1).
Fever clearance [median (range)] in the 10 women
febrileonadmissionwasrapidandsimilarforbothgroups:
group 1 (i.v.ﬁrst):1 (1–2) vs. group 2 (oral ﬁrst):1(1) day,P =
0.414. Parasite clearance was also rapid and not signiﬁ-
cantly different: group 1, 2 (1–4) days vs. group 2, 1 (1–2)
days, P = 0.084.The parasite clearance time was 1.5 (1–4)
days in the 16 women without recrudescence vs. 2.5 days
(1–4) in the two women with PCR conﬁrmed recrudes-
cence, P = 0.587. There were no suspected drug related
adverseevents.Symptomsonadmission(headache85.0%,
joint pain, dizziness and fatigue 75% and anorexia 60.0%)
all resolved rapidly with treatment. The treatment was
very well tolerated and no signiﬁcant side effects were
reported. One patient was transfused on day 7 for severe
anaemia as her haematocrit fell from 25% on admission to
18% on day 6. After excluding women with haematocrit
values taken on or after a reappearance or transfusion,the
median (range) difference in haematocrit was signiﬁcantly
lower than baseline at day 7,-2.2 (-7.0 to 8.0)%,P = 0.019,
but was signiﬁcantly higher than baseline by day 35, +2.0
(0 to 5.0)%,P = 0.042.
White blood cell and platelet count [median (range)
(¥10
3/ml)] improved signiﬁcantly from day 0 to day 14: 6.2
(1.5–9.7) vs. 9.6 (6.8–17.1), P = 0.001; 130 (39–278) vs. 284
(24–492), P = 0.002. No adverse effect on biochemical
parameters was observed following treatment (data not
shown).
Pregnancy outcome
Three women were lost to follow-up before the outcome
of pregnancy was known. The remaining 17 women all
delivered live born, normal, singleton babies at a median
gestation of 39.2 (35.6–41.5) weeks. There were 11.8%
(2/17) premature births.Most of these infants 59% (10/17)
were born at home. All 17 babies were weighed but only
seven were weighed within 72 h of birth. They had a
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Figure 2
Dose-normalized DHA exposure (AUC(0,•)/dose) at day 0 and day 1 vs. DHA exposure at day 6 after repeated oral administration of artesunate (4 mg kg
-1
day
-1) in pregnant women with malaria (A) and in the same women post partum in a healthy state (B)
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were of low birth weight (<2500 g). No congenital abnor-
malities were detected by newborn examination. One
infant went back to Myanmar after delivery, 12 of the
remaining16werefollowedupto1yearandfourwerelost
to follow-up after 4, 6, 10 and 11 months. All infants had
achieved normal developmental milestones at their last
assessment.
Discussion
This is the most detailed examination of the pharmacoki-
netic properties of ARS in pregnancy conducted to date
and it shows that the effects of malaria on oral drug dis-
position are greater than those of pregnancy. Following
oral administration of ARS plasma concentrations of ARS
and its main biologically active metabolite, DHA, were
higher in pregnant women with acute malaria compared
with those in the same women post partum in a healthy
state. This was because of increased oral bioavailability,
which conﬁrms that acute malaria substantially reduces
the pre-systemic biotransformation of ARS. Oral ARS is
hydrolyzed rapidly in the stomach to the biologically
active metabolite DHA and this is inactivated by glucu-
ronidation. DHA concentrations were increased as well
suggesting a disease related reduction in ﬁrst-pass glucu-
ronidation. This was reinforced by the signiﬁcant reduc-
tion in plasma concentrations on day 6 observed in acute
malaria (when there had been considerable recovery) but
Table 2
Non-compartmental analysis of ARS and DHA pharmacokinetics in pregnant women with malaria and in the same women post partum in a healthy state
(A) i.v. administration
ARS DHA
Pregnant (n = 20) Post partum (n = 14) P value Pregnant (n = 20) Post partum (n = 14) P value
Body weight (kg) 48.0 (40.0–64.0) 46.5 (37.0–52.0) 0.011 48.0 (40.0–64.0) 46.5 (37.0–52.0) 0.011
Dose (mg kg-1) 4.00 (3.33–4.05) 4.00 (3.96–4.05) 0.232 2.96 (2.47–3.00) 2.96 (2.93–3.00) 0.232
Number of points lambda 3.00 (3.00–5.00) 3.00 (3.00–5.00) 0.359 4.00 (4.00–6.00) 5.00 (4.00–5.00) 0.014
C0 (ng ml-1) 15 700 (3 860–28 700) 12 200 (5 490–23 900) 0.975 3210 (1570–4360) 2930 (856–3980) 0.272
C0/dose (ng ml-1/mg kg-1) 3 910 (976–7 110) 3 070 (1 390–5 900) 0.925 1110 (535–1450) 984 (292–1340) 0.246
CL (l h-1) 196.0 (101.0–410.0) 213.0 (81.5–467.0) 0.730 60.6 (32.8–107.0) 61.9 (35.3–99.7) 0.925
CL (l h-1 kg-1) 4.19 (2.29–10.20) 5.05 (2.20–9.93) 0.551 1.20 (0.683–2.14) 1.35 (0.905–1.99) 0.470
V (l) 35.6 (17.0–208.0) 53.3 (22.3–94.6) 0.594 87.5 (40.5–196.0) 108 (44.9–225.0) 0.300
V (l kg-1) 0.76 (0.39–4.15) 1.18 (0.46–1.89) 0.594 1.76 (0.84–3.92) 2.37 (1.15–4.51) 0.124
t1/2 (h) 0.12 (0.11–0.61) 0.13 (0.11–0.42) 0.730 1.03 (0.65–1.46) 1.15 (0.88–1.57) 0.074
AUC(0,•) (ng ml-1 h) 955 (395–1 735) 792 (398–1 840) 0.975 2450 (1370–4340) 2220 (1470–3270) 0.363
AUC(0,•)/dose (ng ml-1 h/mg kg-1) 239 (98–437) 198 (101–454) 0.875 831 (467–1460) 741 (502–1100) 0.246
Back ext. AUC (%) 68.5 (32.3–76.6) 71.2 (51.2–76.2) 0.826 10.1 (5.3–15.7) 9.7 (4.8–13.1) 0.925
Ext. AUC (%) 0.05 (0.02–0.28) 0.06 (0.03–0.20) 0.551 0.92 (0.15–2.80) 1.80 (0.69–5.79) 0.022
(B) oral administration
ARS DHA
Pregnant (n = 20) Post partum (n = 14) P value Pregnant (n = 19) Post partum (n = 14) P value
Body weight (kg) 48.0 (40.0–64.0) 47.0 (37.0–52.0) 0.015 48.0 (40.0–64.0) 46.5 (37.0–52.0) 0.015
Dose (mg kg-1) 3.99 (3.87–4.09) 3.99 (3.85–4.33) 0.972 2.96 (2.87–3.03) 2.96 (2.85–3.21) 0.972
Number of points lambda 4 (3–5) 3 (3–5) 0.157 4 (3–5) 4 (3–5) 0.272
Cmax (ng ml-1) 212 (30–1 240) 119 (35–326) 0.055 1040 (635–2110) 915 (384–2090) 0.133
Cmax/dose (ng ml-1/mg kg-1) 52.9 (7.8–310.0) 30.9 (8.9–80.4) 0.033 351 (219–712) 307 (133–652) 0.152
tmax (h) 1.00 (0.22–1.55) 1.00 (0.25–2.00) 0.140 1.50 (0.50–3.05) 1.50 (0.50–3.00) 0.527
CL/F (l h-1) 877 (545–1 540) 1 640 (792–3 940) 0.002 75.8 (35.3–128) 89.8 (55.1–128) 0.039
CL/F (l h-1 kg-1) 17.8 (10.3–34.2) 37.8 (18.4–82.1) 0.002 1.53 (0.88–2.57) 1.91 (1.38–2.85) 0.013
V/F (l) 503 (102–5 420) 643 (173–1 810) 0.087 94 (50–295) 137 (57–196) 0.033
V/F (l kg-1) 10.2 (2.03–113.0) 13.1 (4.67–40.1) 0.087 1.91 (1.13–5.91) 2.87 (1.45–4.17) 0.033
t1/2 (h) 0.35 (0.10–4.32) 0.24 (0.13-0.62) 0.916 0.86 (0.67–1.59) 1.02 (0.71–1.30) 0.279
AUC(0,•) (ng ml-1 h) 217 (117–392) 106 (48–221) 0.003 1940 (1140–3400) 1550 (1010–2180) 0.007
AUC(0,•)/dose (ng ml-1 h/mg kg-1) 55.1 (30.1–100) 26.5 (12.2–54.3) 0.002 673 (386–1130) 523 (351–724) 0.007
Ext. AUC (%) 1.08 (0.21–40.60) 0.87 (0.16–3.10) 0.701 1.78 (0.52–3.94) 2.70 (1.56–5.71) 0.133
F (%) 21.7 (12.6–75.1) 9.86 (6.0–36.8) 0.046 77.0 (42.2–129.0) 72.7 (42.0–87.7) 0.033
All estimates are given as median (range). P values are given using the Wilcoxon matched-pairs signed-ranks test. Number of points lambda number of observations used in the
log-linear regression in the terminal elimination phase, C0 initial predicted plasma concentration after i.v. administration, Cmax maximum observed plasma concentration after oral
administration, tmax observed time to reach Cmax, CL clearance, V volume of distribution, t1/2 terminal elimination half-life, AUC(0,•) predicted area under the plasma concentration–
time curve after the last dose from zero time to inﬁnity, Back ext. AUC percentage of AUC(0,•) back-extrapolated from the ﬁrst observation to time zero, Ext. AUC percentage of
AUC(0,•) extrapolated from the last observation to inﬁnity and F (%) oral bioavailability.
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period when healthy (Table 3). This argues for a disease
effect and not an effect related to autoinduction of
metabolism, although in this study precise separation of
the effects of disease and pregnancy was not possible.
The pharmacokinetic properties of i.v. ARS overall were
similar in pregnancy and in the same women post
partum in a healthy state and neither pregnancy nor
disease had a major effect on the disposition of ARS or
DHA. However assessment of pharmacokinetic variables
by disease severity showed a signiﬁcantly higher drug
exposure in the group of women who were more unwell
indicating that disease severity does reduce drug clear-
ance.This is reassuring for the treatment of severe malaria
in pregnancy with parenteral ARS as there had been
concern, based on earlier studies, that drug concentra-
tions and therefore therapeutic responses might be
reduced and doses might have to be increased.
From a therapeutic standpoint ARS can be considered
as a pro-drug contributing only a small proportion of the
overall parasiticidal effect. ARS is readily hydrolyzed at
acid and neutral pH to the active metabolite DHA, and
the active metabolite is inactivated by pre-systemic glu-
curonidation. Concentrations of both parent compound
and metabolite are increased in acute malaria [10, 17]. A
large portion of orally administered ARS is hydrolyzed in
the stomach and absorbed as DHA. In this study the
plasma exposure of ARS following oral administration
was approximately four times lower than that following
i.v. administration. Elimination of ARS from the blood fol-
lowing oral administration is determined by the rate of
absorption. This reﬂected in an approximately three fold
longer terminal elimination half-life after oral administra-
tion (i.e. ﬂip-ﬂop kinetics). However, this difference in ter-
minal elimination half-life might be an artifact of more
data below the limit of quantiﬁcation after i.v.administra-
tion compared with oral administration biasing the log-
linear regression. This might also explain the lack of a
signiﬁcant difference in ARS volume of distribution in
pregnant and non-pregnant women after oral administra-
tion. Following i.v. administration in women post partum
in a healthy state, median clearance of ARS was 213 l h
-1
while the liver blood ﬂow was only approximately 90 l h
-1
(and is reduced in acute malaria [18]). This suggests that
the majority of clearance is through de-esteriﬁcation and
degradation in the blood. However in terms of therapeu-
tic responses it is the DHA concentrations which contrib-
ute the majority of effect and these were relatively
unaffected.
Thisstudydidnotconﬁrmpreviousreportsthatplasma
concentrations of the artemisinin derivatives were sub-
stantially reduced in pregnant women with acute malaria
[3, 4]. Both of the previous reports compared concen-
trations in uncomplicated malaria in pregnancy to non-
pregnant adult concentrations. Furthermore drug
concentrations were quantiﬁed with a different method
from that in this study. It is possible therefore that meth-
odological problems related to drug analysis may have
contributed to the differences between the earlier studies
andtheresultsofthepresentstudy.Plasmaconcentrations
of both ARS and dihydroartemisinin may be apparently
reduced in acute malaria if there are haemolytic blood
products(whichareusualinmalaria)inthesampleandthe
analytical method fails to compensate for ex vivo decom-
position of the peroxides [12].The data from the present
study are reassuring regarding current dosing recommen-
dations for ARS in pregnancy. This study identiﬁes the
cause of altered ARS pharmacokinetics in acute malaria in
Table 3
Statistical comparison of DHA pharmacokinetics between day 0 and day 1 vs. day 6 after oral administration of artesunate in pregnant women with
uncomplicated malaria and in the same women post partum in a healthy state*
DHA Day 0 and Day 1 DHA Day 6 Ratio Day0 and 1 : Day6 P value
Pregnant women n = 19 n = 19 n = 19
Cmax/dose (ng ml-1/mg kg-1) 329.0 (92.5–664.0) 191.0 (69.8–399.0) 1.97 (0.34–5.27) 0.007
tmax (h) 1.00 (0.97–2.03) 1.05 (0.983–2.10) 1.00 (0.50–2.00) 0.565
CL/F (l h-1 kg-1) 1.65 (0.90–3.57) 3.06 (1.82–6.38) 0.55 (0.19–1.21) <0.001
V/F (l kg-1) 2.23 (1.11–5.95) 4.00 (2.00–8.29) 0.54 (0.15–2.34) 0.004
t1/2 (h) 0.84 (0.66–1.47) 0.84 (0.63–1.34) 0.98 (0.81–2.32) 0.968
AUC(0,•)/dose ( ng ml-1 h/mg kg-1) 605 (356–1120) 327 (157–550) 1.83 (0.83–5.28) <0.001
Post partum women n = 12 n = 12 n = 12
Cmax/dose (ng ml-1/(mg kg-1)] 231 (133–404) 152 (74–324) 1.39 (0.59–2.82) 0.182
tmax (h) 1.00 (1.00–2.00) 1.58 (1.00–4.00) 0.93 (0.25–2.00) 0.523
CL/F (l h-1 kg-1) 2.30 (1.28–3.22) 2.52 (1.79–4.17) 0.86 (0.42–1.32) 0.136
V/F (l kg-1) 3.32 (1.85–4.33) 3.46 (2.60–8.33) 0.92 (0.40–1.23) 0.117
t1/2 (h) 1.00 (0.76–1.26) 1.04 (0.78–1.50) 0.95 (0.76–1.41) 0.347
AUC(0,•)/dose (ng ml-1 h/mg kg-1) 435 (311–779) 397 (240–557) 1.17 (0.76–2.38) 0.084
*Non-compartmental analysis was performed using drug concentrations measured at the same time points (i.e. 1, 2, 4 and 6 h after dose) at day 0, day 1 and day 6 for all groups.
Data are median (range). Cmax, maximum observed plasma concentration after oral administration, tmax, observed time to reach Cmax, CL clearance, V, volume of distribution, t1/2,
terminal elimination half-life, AUC(0,•), predicted area under the plasma concentration–time curve after the last dose from zero time to inﬁnity and F, oral bioavailability.
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Table 4
Statistical comparison of ARS and DHA pharmacokinetics in mildly and moderately unwell pregnant women with uncomplicated malaria
(a) i.v. administration
ARS DHA
Mildly unwell
(n = 7)
Moderately unwell
(n = 13) P value
Mildly unwell
(n = 7)
Moderately unwell
(n = 13) P value
Body weight (kg) 50.0 (42.0–59.0) 48.0 (40.0–64.0) 0.605 50.0 (42.0–59.0) 48.0 (40.0–64.0) 0.605
Dose (mg kg-1) 3.97 (3.96–4.00) 4.03 (3.33–4.05) 0.039 2.94 (2.93–2.96) 2.99 (2.47–3.00) 0.039
Number of points lambda 3 (3–5) 3 (3–4) 0.202 4 (4–5) 5 (4–6) 0.259
C0 (ng ml-1) 10 900 (3 860–21 500) 16 900 (6 140–28 700) 0.191 3030 (1570–3780) 3240 (2510–4360) 0.362
C0/dose (ng ml-1/mg kg-1) 2 730 (976–5 430) 4 160 (1 520–7 110) 0.166 1020 (535–1290) 1140 (850–1450) 0.251
CL (l h-1) 246 (159–273) 182 (101–410) 0.104 71 (55–107) 48 (33–66) 0.005
CL (l h-1 kg-1) 4.63 (3.20–5.85) 3.86 (2.29–10.20) 0.166 1.55 (1.23–2.14) 1.07 (0.68–1.48) 0.001
V (l) 40.9 (27.2–208.0) 33.1 (17.0–165.0) 0.143 112.0 (77.7–196) 71.1 (40.5–130.0) 0.016
V (l kg-1) 0.97 (0.54–4.15) 0.68 (0.39–3.36) 0.104 2.33 (1.85–3.92) 1.49 (0.84–2.54) 0.005
t1/2 (h) 0.12 (0.11–0.54) 0.12 (0.11–0.61) 0.552 1.12 (0.78–1.27) 0.98 (0.65–1.46) 0.285
AUC(0,•) (ng ml-1 h) 856 (684–1 240) 446 (395–1 730) 0.219 1890 (1370–2410) 2670 (2010–4340) 0.001
AUC(0,•)/dose (ng ml-1 h/mg kg-1) 216 (171–314) 259 (98–437) 0.166 645 (467–815) 932 (677–1460) 0.001
Back ext. AUC (%) 70.1 (32.3–75.7) 70.9 (61.2–76.6) 0.501 10.3 (7.45–15.7) 9.90 (5.33–14.2) 0.607
Ext. AUC (%) 0.04 (0.03–0.28) 0.06 (0.02–0.18) 0.663 1.20 (0.27–2.24) 0.91 (0.15–2.80) 0.874
(b) oral administration
ARS DHA
Mildly unwell
(n = 7)
Moderately unwell
(n = 13) P value
Mildly unwell
(n = 7)
Moderately unwell
(n = 12) P value
Body weight (kg) 50.0 (42.0–59.0) 48.0 (40.0–64.0) 0.605 50.0 (42.0–59.0) 47.0 (40.0–64.0) 0.641
Dose (mg kg-1) 4.00 (3.87–4.03) 3.99 (3.98–4.09) 0.300 2.93 (2.87–2.98) 2.98 (2.88–3.03) 0.234
Number of points lambda 3 (3–4) 4 (3–5) 0.035 4 (3–5) 4 (3–5) 0.154
Cmax(ng ml-1) 170 (86.4–1 240) 226 (30.4–637) 0.552 975 (635–2110) 1180 (706–2000) 0.353
Cmax/dose (ng ml-1/(mg kg-1) 43.9 (21.5–310) 57.3 (7.78–157) 0.552 329 (219–712) 388 (234–664) 0.398
tmax (h) 1.00 (0.22–1.07) 1.00 (0.25–1.55) 0.775 1.00 (0.50–3.05) 1.50 (0.50–2.00) 0.602
CL/F (l h-1) 1 000 (634–1 400) 870 (545–1 540) 0.405 85 (72–128) 70 (35–101) 0.023
CL/F (l h-1 kg-1) 17.0 (12.7–29.2) 18.1 (10.3–34.2) 0.663 1.8 (1.4–2.6) 1.4 (0.9–2.5) 0.028
V/F (l) 372 (102–907) 176 (176–5 420) 0.501 128 (74–295) 85 (50–123) 0.014
V/F (l kg-1) 8.3 (2.0–15.4) 10.3 (3.9–113.0) 0.362 2.6 (1.6–5.9) 1.7 (1.1–2.6) 0.018
t1/2 (h) 0.26 (0.09–0.79) 0.36 (0.22–4.32) 0.322 1.02 (0.67–1.59) 0.84 (0.69–1.07) 0.447
AUC(0,•) (ng ml-1 h) 233 (137–312) 207 (117–392) 0.663 1610 (1140–2040) 2180 (1190–3400) 0.023
AUC(0,•)/dose (ng ml-1 h/mg kg-1) 58 (35–78) 52 (30–100) 0.663 542 (386–687) 721 (394–1130) 0.028
Ext. AUC (%) 1.21 (0.21–21.70) 0.95 (0.37–40.60) 0.905 2.60 (0.52–3.72) 1.41 (0.59–3.94) 0.612
F (%) 26.8 (12.6–37.7) 21.7 (13.5–75.0) 0.501 77.0 (71.1–107.0) 78.7 (42.3–129.0) 0.800
All estimates are given as median (range). P values are given using the two-sample Wilcoxon rank-sum (Mann-Whitney) test. Number of points lambda number of observations used
in the log-linear regression in the terminal elimination phase, C0 initial predicted plasma concentration after i.v. administration, Cmax maximum observed plasma concentration after
oral administration, tmax observed time to reach Cmax, CL clearance, V volume of distribution, t1/2 terminal elimination half-life, AUC(0,•) predicted area under the plasma
concentration–time curve after the last dose from zero time to inﬁnity, Back ext. AUC percentage of AUC(0,•) back-extrapolated from the ﬁrst observation to time zero, Ext. AUC
percentage of AUC(0,•) extrapolated from the last observation to inﬁnity and F (%) oral bioavailability.
ARS and DHA pharmacokinetics in pregnancy
Br J Clin Pharmacol / 73:3 / 475administrative staff from SMRU and Mahidol Oxford
Research Unit (MORU) in Bangkok.
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Figure 3
Combined drug exposure of ARS and DHA to illustrate antimalarial effect concentrations in pregnant women treated with intravenous and oral artesunate
who were mildly or moderately unwell with uncomplicated malaria
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